Ubs Asset Management Americas Inc Crispr Therapeutics Ag Transaction History

Ubs Asset Management Americas Inc

$379 Billion
Q1 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 1,952,751 shares of CRSP stock, worth $110 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,952,751

Previous 690,191 182.93%

Holding current value

$110 Million

Previous $27.2 Million 144.62%

% of portfolio

0.02%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 19, 2025	BUY	$34.03 - $53.02 $43 Million - $66.9 Million	1,262,560 Added 182.93%	1,952,751 $66.5 Million
Q4 2024 Feb 14, 2025	BUY	$38.65 - $55.15 $535,882 - $764,654	13,865 Added 2.05%	690,191 $27.2 Million
Q3 2024 Nov 14, 2024	SELL	$44.62 - $62.75 $786,739 - $1.11 Million	-17,632 Reduced 2.54%	676,326 $31.8 Million
Q2 2024 Aug 13, 2024	BUY	$51.17 - $68.18 $29.9 Million - $39.8 Million	583,493 Added 528.22%	693,958 $37.5 Million
Q1 2024 May 15, 2024	BUY	$60.67 - $89.12 $880,625 - $1.29 Million	14,515 Added 15.13%	110,465 $7.53 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $109,101 - $203,908	2,825 Added 3.03%	95,950 $6.01 Million
Q3 2023 Nov 13, 2023	BUY	$45.39 - $59.0 $491,982 - $639,501	10,839 Added 13.17%	93,125 $4.23 Million
Q1 2023 May 15, 2023	BUY	$41.0 - $56.12 $261,580 - $358,045	6,380 Added 8.41%	82,286 $3.72 Million
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $4,702 - $7,880	120 Added 0.16%	75,906 $3.09 Million
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $3.51 Million - $4.81 Million	-57,368 Reduced 43.08%	75,786 $4.95 Million
Q2 2022 Aug 12, 2022	BUY	$43.23 - $73.83 $597,741 - $1.02 Million	13,827 Added 11.59%	133,154 $8.09 Million
Q1 2022 May 16, 2022	SELL	$53.19 - $79.24 $10,957 - $16,323	-206 Reduced 0.17%	119,327 $7.49 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $358,370 - $569,025	5,113 Added 4.47%	119,533 $9.06 Million
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $307,788 - $437,495	-2,793 Reduced 2.38%	114,420 $12.8 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $2.4 Million - $3.86 Million	-23,841 Reduced 16.9%	117,213 $19 Million
Q1 2021 May 14, 2021	BUY	$110.72 - $210.04 $3.8 Million - $7.21 Million	34,308 Added 32.14%	141,054 $17.2 Million
Q4 2020 Mar 01, 2021	SELL	$79.67 - $173.23 $1.1 Million - $2.4 Million	-13,846 Reduced 11.48%	106,746 $16.3 Million
Q3 2020 Nov 13, 2020	SELL	$78.5 - $100.64 $1.45 Million - $1.86 Million	-18,438 Reduced 13.26%	120,592 $10.1 Million
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $335,027 - $661,787	8,702 Added 6.68%	139,030 $10.2 Million
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $4.39 Million - $8.15 Million	130,328 New	130,328 $5.53 Million

Others Institutions Holding CRSP

# of Institutions

491

Shares Held

64.7M

Call Options Held

2.16M

Put Options Held

2.1M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.4B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Crispr Therapeutics Ag Transaction History